Home Tags Targeted Therapies

Tag: Targeted Therapies

AstraZeneca to Invest $1.5 billion in the Company’s first-ever Facility for...

AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.

FDA Clears IND Application for a Phase 1/2 Study of OBI-992...

The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-992 (also known as BSI-992), to conduct a...

A Fantastic Voyage: From Magic Bullet to Antibody-drug Conjugate

Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer (and potentially other diseases). However, unlike chemotherapy, ADCs are intended to directly target and kill tumor cells while, at the same time sparing normal, healthy cells.

X